Cargando…
Application of Immuno-PET in Antibody–Drug Conjugate Development
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determini...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207972/ https://www.ncbi.nlm.nih.gov/pubmed/30370812 http://dx.doi.org/10.1177/1536012118801223 |
_version_ | 1783366623569117184 |
---|---|
author | Carmon, Kendra S. Azhdarinia, Ali |
author_facet | Carmon, Kendra S. Azhdarinia, Ali |
author_sort | Carmon, Kendra S. |
collection | PubMed |
description | Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determining drug effects. Positron emission tomography (PET) imaging using zirconium-89 radiolabeled monoclonal antibodies (mAbs), also referred to as zirconium-89 ((89)Zr)-immuno-PET, provides a potential biomarker to measure target expression and verify optimal delivery of targeted agents to tumors. Antibody–drug conjugates (ADCs) combine the high affinity and specificity of mAbs with the potency of cytotoxic drugs to target tumor-expressing antigen and destroy cancer cells. Thus, (89)Zr-immuno-PET of whole-body biodistribution, pharmacokinetics, and tumor targeting of antibodies and ADCs to predict toxicity and efficacy could help guide individualized treatment. Here, we review how (89)Zr-immuno-PET is being used as a companion diagnostic with the development of ADCs. Furthermore, we discuss how (89)Zr-immuno-PET may be utilized in future clinical trials as an adjunct tool with novel ADCs to select cancer patients who have the greatest potential to benefit from treatment and improve ADC dosing regimens. |
format | Online Article Text |
id | pubmed-6207972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-62079722018-11-05 Application of Immuno-PET in Antibody–Drug Conjugate Development Carmon, Kendra S. Azhdarinia, Ali Mol Imaging Review Article Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determining drug effects. Positron emission tomography (PET) imaging using zirconium-89 radiolabeled monoclonal antibodies (mAbs), also referred to as zirconium-89 ((89)Zr)-immuno-PET, provides a potential biomarker to measure target expression and verify optimal delivery of targeted agents to tumors. Antibody–drug conjugates (ADCs) combine the high affinity and specificity of mAbs with the potency of cytotoxic drugs to target tumor-expressing antigen and destroy cancer cells. Thus, (89)Zr-immuno-PET of whole-body biodistribution, pharmacokinetics, and tumor targeting of antibodies and ADCs to predict toxicity and efficacy could help guide individualized treatment. Here, we review how (89)Zr-immuno-PET is being used as a companion diagnostic with the development of ADCs. Furthermore, we discuss how (89)Zr-immuno-PET may be utilized in future clinical trials as an adjunct tool with novel ADCs to select cancer patients who have the greatest potential to benefit from treatment and improve ADC dosing regimens. SAGE Publications 2018-10-29 /pmc/articles/PMC6207972/ /pubmed/30370812 http://dx.doi.org/10.1177/1536012118801223 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Article Carmon, Kendra S. Azhdarinia, Ali Application of Immuno-PET in Antibody–Drug Conjugate Development |
title | Application of Immuno-PET in Antibody–Drug Conjugate Development |
title_full | Application of Immuno-PET in Antibody–Drug Conjugate Development |
title_fullStr | Application of Immuno-PET in Antibody–Drug Conjugate Development |
title_full_unstemmed | Application of Immuno-PET in Antibody–Drug Conjugate Development |
title_short | Application of Immuno-PET in Antibody–Drug Conjugate Development |
title_sort | application of immuno-pet in antibody–drug conjugate development |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207972/ https://www.ncbi.nlm.nih.gov/pubmed/30370812 http://dx.doi.org/10.1177/1536012118801223 |
work_keys_str_mv | AT carmonkendras applicationofimmunopetinantibodydrugconjugatedevelopment AT azhdariniaali applicationofimmunopetinantibodydrugconjugatedevelopment |